IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Clinical trial NCT05987332 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05987332
- Sponsor
- IDEAYA Biosciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-31
- Primary completion
- 2027-01-15
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.